Haleon (HLN) Asset Writedowns and Impairment (2022 - 2023)
Haleon (HLN) posted Asset Writedowns and Impairment of $7.4 million for Q4 2023, down 72.4% on a QoQ basis from $27.0 million in Q4 2022, and down 72.4% year-over-year from $27.0 million in Q4 2022.
Haleon (HLN) Asset Writedowns and Impairment (2022 - 2023) Analysis & Trends
Haleon's Asset Writedowns and Impairment history runs 2 years deep, the most recent figure standing at $7.4 million for Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 7.45 Mn |
| Dec 31, 2023 | 7.45 Mn |
| Dec 31, 2022 | 26.98 Mn |
| Dec 31, 2022 | 26.98 Mn |